Integrated Computational Approach for Designing Potent EGFR-TK Inhibitors: QSAR, Docking, ADMET, and Molecular...

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Cancer Therapeutics

Background:

• Epidermal Growth Factor Receptor (EGFR) is a key target in cancer therapy.
• Existing EGFR tyrosine kinase inhibitors (TKIs) face challenges with drug resistance and toxicity.
• Optimized pharmacophores and novel chemical entities (NCEs) are needed to overcome these limitations.

Purpose of the Study:

• To develop a 3D quantitative structure-activity relationship (QSAR) model for optimizing EGFR inhibitor pharmacophores.
• To design and evaluate novel chemical entities (NCEs) with improved anticancer properties.
• To assess the drug-likeness, stability, and binding affinity of designed NCEs to EGFR.

Main Methods:

• QSAR models were constructed using 42 thiazolyl-pyrazoline derivatives in Schrödinger Maestro v13.4.
• Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiling was performed using QikProp.
• Molecular docking and 100 ns molecular dynamics simulations were conducted using Desmond to assess binding stability and interactions.

Main Results:

• A significant QSAR model was established (R² = 0.7880, Q² = 0.7341).
• Forty NCEs with favorable drug-like properties were identified.
• NCE 2 exhibited a high docking score (-8.178 kcal/mol) and stable interaction with the EGFR binding site (RMSD 2.4–2.8 Å).

Conclusions:

• NCE 2, a novel thiazolyl-pyrazoline derivative, demonstrates significant EGFR inhibitory activity.
• The compound possesses favorable ADMET properties and structural stability.
• NCE 2 represents a promising candidate for further preclinical development as an anticancer agent.